EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Bacterial Conjunctivitis - Pipeline Review, H1 2015

  • ID: 3259637
  • Report
  • April 2015
  • 53 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Cellceutix Corporation
  • Ocular Therapeutix, Inc.
  • MORE
Bacterial Conjunctivitis - Pipeline Review, H1 2015

Summary

This, ‘Bacterial Conjunctivitis - Pipeline Review, H1 2015’, provides an overview of the Bacterial Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bacterial Conjunctivitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bacterial Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bacterial Conjunctivitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bacterial Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cellceutix Corporation
  • Ocular Therapeutix, Inc.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Bacterial Conjunctivitis Overview
Therapeutics Development
Pipeline Products for Bacterial Conjunctivitis - Overview
Pipeline Products for Bacterial Conjunctivitis - Comparative Analysis
Bacterial Conjunctivitis - Therapeutics under Development by Companies
Bacterial Conjunctivitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bacterial Conjunctivitis - Products under Development by Companies
Bacterial Conjunctivitis - Companies Involved in Therapeutics Development
Cellceutix Corporation
China Grand Wuhan General Pharmaceutical Research Institute
Daiichi Sankyo Company, Limited
InSite Vision Incorporated
NovaBay Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Bacterial Conjunctivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
auriclosene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISV-405 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
moxifloxacin hydrochloride SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-638 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-704 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-727 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XY-0911AQ2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bacterial Conjunctivitis - Recent Pipeline Updates
Bacterial Conjunctivitis - Dormant Projects
Bacterial Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US
Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops
Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bacterial Conjunctivitis, H1 2015
Number of Products under Development for Bacterial Conjunctivitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Bacterial Conjunctivitis - Pipeline by Cellceutix Corporation, H1 2015
Bacterial Conjunctivitis - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H1 2015
Bacterial Conjunctivitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Bacterial Conjunctivitis - Pipeline by InSite Vision Incorporated, H1 2015
Bacterial Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015
Bacterial Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Bacterial Conjunctivitis Therapeutics - Recent Pipeline Updates, H1 2015
Bacterial Conjunctivitis - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Bacterial Conjunctivitis, H1 2015
Number of Products under Development for Bacterial Conjunctivitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Cellceutix Corporation
China Grand Wuhan General Pharmaceutical Research Institute
Daiichi Sankyo Company, Limited
InSite Vision Incorporated
NovaBay Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll